Sign In
Buy LPCN
$2.12
+0.0100 (+0.474%)
At Close: Jul 31, 2026
Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study
06:30am, Wednesday, 25'th Aug 2021
SALT LAKE CITY, Aug. 25, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36
Lipocine Stock Jumps On Litigation Settlement With Clarus Therapeutics
06:03am, Thursday, 15'th Jul 2021
Lipocine Inc (NASDAQ: LPCN) has entered into a settlement and license agreement with Clarus Therapeutics to resolve claims in the ongoing intellectual property litigation and interference proceed
Lipocine Announces Settlement With Clarus Therapeutics
04:00pm, Wednesday, 14'th Jul 2021
SALT LAKE CITY, July 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered
Lipocine To Present At The Ladenburg Thalmann Healthcare Conference
08:00am, Tuesday, 06'th Jul 2021
SALT LAKE CITY, July 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company wi
Lipocine To Present At The Raymond James Human Health Innovation Conference
08:00am, Wednesday, 16'th Jun 2021
SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company w
Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression Patients
09:37am, Monday, 14'th Jun 2021
The FDA has signed off Lipocine Inc's (NASDAQ: LPCN) Investigational New Drug Application (IND) to initiate a Phase 2 study to evaluate LPCN 1154 for the treatment of postpartum depression (PPD) in
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
08:00am, Monday, 14'th Jun 2021
SALT LAKE CITY, June 14, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food
Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference
08:00am, Monday, 07'th Jun 2021
SALT LAKE CITY, June 7, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company wi
Summary Judgment Ruling in Patent Infringement Lawsuit
08:00am, Wednesday, 26'th May 2021
SALT LAKE CITY, May 26, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United Sta
Clarus Therapeutics Defeats Lipocine's Patent Infringement Lawsuit On Summary Judgment
08:32pm, Tuesday, 25'th May 2021
NORTHBROOK, Ill., May 25, 2021 /PRNewswire/ -- Today, Federal Circuit Judge William C.
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021
08:00am, Thursday, 06'th May 2021
SALT LAKE CITY, May 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results fo
7 Reddit Penny Stocks to Keep Your Eye on for Big Movement
01:07pm, Wednesday, 24'th Mar 2021
Reddit stocks -- and in particular Reddit penny stocks -- are some of the riskiest shares out there. Yet, investors could make out big with some of the names on this list.
Top Penny Stocks News Today: TNXP, ONTX, AREC, LPCN and ZCMD
02:59pm, Wednesday, 17'th Mar 2021
Amid risk-on sentiment, penny stocks are surging higher today as investors seek to grab the higher upside these small-cap stocks provide. The post Top Penny Stocks News Today: TNXP, ONTX, AREC, LPCN a
Lipocine Announces Financial Results For The Year Ended December 31, 2020
08:00am, Thursday, 11'th Mar 2021
SALT LAKE CITY, March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results
Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics
08:00am, Tuesday, 29'th Dec 2020
SALT LAKE CITY, Dec. 29, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William
